伦瓦提尼
索拉非尼
医学
甲状腺癌
耐火材料(行星科学)
肿瘤科
内科学
不利影响
临床试验
疾病
安慰剂
甲状腺
病理
替代医学
物理
肝细胞癌
天体生物学
作者
Naoki Fukuda,Shunji Takahashi
出处
期刊:Cancers
[Multidisciplinary Digital Publishing Institute]
日期:2021-05-10
卷期号:13 (9): 2279-2279
被引量:23
标识
DOI:10.3390/cancers13092279
摘要
Differentiated thyroid cancer is usually a slow-growing disease, even if the patients develop distant metastasis. For recurrent or metastatic disease, radioactive iodine therapy is a standard treatment. However, the disease gradually progresses in some of the patients and can ultimately develop into life-threatening conditions. For patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RR-DTC), multi-kinase inhibitors (MKIs) including sorafenib and lenvatinib prolonged progression-free survival compared with placebo in pivotal randomized phase 3 trials, although the benefit in overall survival has not been clearly confirmed, possibly because the patients who received placebo were permitted to cross-over to lenvatinib upon disease progression. Moreover, the adverse events related to MKIs were not negligible. Therefore, the optimal timing of MKI initiation has long been controversial, and physicians should consider various patient and disease factors. Herein, we comprehensively review the clinical factors that can be helpful in determining the initiation of MKIs for patients with RR-DTC.
科研通智能强力驱动
Strongly Powered by AbleSci AI